Health & bio

Veppanu (vepdegestrant) first PROTAC FDA approval

Arvinas and Pfizer for ER+/HER2-/ESR1 mutation advanced breast cancer.

Primary sources · 1
BioPharma Watch
← View the full 2026-05-05 (Tuesday) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →